The FDA sends warning letters to manufacturers of medical devices when there is concern for product safety or reliability, creating negative publicity. In 2004, the FDA sent a warning letter to Johnson & Johnson's Cordis, identifying safety concerns in its manufacturing plants. This created negative publicity which has slowed the growth of this franchise until follow-inspections resolved the issue in 2006.
Like products of other major drugmakers, most of Johnson & Johnson's pharmaceutical products has been or will eventually be affected by generic medications. The U.S. patent for Risperdal, the company's most profitable drug, will expire in the end of 2007, and sales are likely to decline significantly after the loss of patent protection.